Marinus Pharmaceuticals’ Ganaxolone IV Demonstrates Robust Efficacy in Benzodiazepine-Resistant Model of Status Epilepticus
Data Presented at the American Academy of Neurology Annual Meeting Phase 1 Clinical Program On-Track to Initiate in 1H 2016 RADNOR, Pa., April 19, 2016 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated …